Anita Cservenka1, Megan M Yardley2, Lara A Ray2,3,4. 1. School of Psychological Science, Oregon State University, Corvallis, Oregon. 2. Department of Psychology, University of California, Los Angeles, California. 3. Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, California. 4. Brain Research Institute, University of California, Los Angeles, California.
Abstract
BACKGROUND AND OBJECTIVES: Pharmacogenetic studies of alcohol use disorder (AUD) have suggested that the efficacy of treatments for AUD is, in part, influenced by the genetic background of an individual. Since the frequency of alleles associated with pharmacotherapy for AUD varies by ancestral background, the effectiveness of medications used to treat AUD may vary among different populations. The purpose of this review is to summarize the existing pharmacogenetic studies of treatments for AUD in individuals of European, East Asian, African, and American Indian/Alaska Native ancestry. METHODS: Electronic databases were searched for pharmacogenetic studies of AUD treatment that included individuals of diverse ancestral backgrounds. RESULTS: Pharmacogenetic studies of AUD reviewed here have primarily investigated genetic variation thought to play a role in the response to naltrexone, ondansetron, and topiramate. There is support that the A118G polymorphism should be further investigated in individuals of East Asian ancestry. DISCUSSION AND CONCLUSIONS: Given the lack of pharmacogenetic research on response to AUD medication in ethnic minority populations and the mixed results, there is a critical need for future studies among individuals of different ancestries. More efforts should be devoted to standardizing procedures such that results can be more readily integrated into a body of literature that can directly inform clinical practice. SCIENTIFIC SIGNIFICANCE: This review highlights the importance for future research to aim for inclusiveness in pharmacogenetic studies of AUD and increase diversity of clinical trials in order to provide the best treatment outcomes for individuals across different racial and ethnic groups. (Am J Addict 2017;26:516-525).
BACKGROUND AND OBJECTIVES: Pharmacogenetic studies of alcohol use disorder (AUD) have suggested that the efficacy of treatments for AUD is, in part, influenced by the genetic background of an individual. Since the frequency of alleles associated with pharmacotherapy for AUD varies by ancestral background, the effectiveness of medications used to treat AUD may vary among different populations. The purpose of this review is to summarize the existing pharmacogenetic studies of treatments for AUD in individuals of European, East Asian, African, and American Indian/Alaska Native ancestry. METHODS: Electronic databases were searched for pharmacogenetic studies of AUD treatment that included individuals of diverse ancestral backgrounds. RESULTS: Pharmacogenetic studies of AUD reviewed here have primarily investigated genetic variation thought to play a role in the response to naltrexone, ondansetron, and topiramate. There is support that the A118G polymorphism should be further investigated in individuals of East Asian ancestry. DISCUSSION AND CONCLUSIONS: Given the lack of pharmacogenetic research on response to AUD medication in ethnic minority populations and the mixed results, there is a critical need for future studies among individuals of different ancestries. More efforts should be devoted to standardizing procedures such that results can be more readily integrated into a body of literature that can directly inform clinical practice. SCIENTIFIC SIGNIFICANCE: This review highlights the importance for future research to aim for inclusiveness in pharmacogenetic studies of AUD and increase diversity of clinical trials in order to provide the best treatment outcomes for individuals across different racial and ethnic groups. (Am J Addict 2017;26:516-525).
Authors: Chupong Ittiwut; Bao-Zhu Yang; Henry R Kranzler; Raymond F Anton; Rungnapa Hirunsatit; Roger D Weiss; Jonathan Covault; Lindsay A Farrer; Joel Gelernter Journal: Alcohol Clin Exp Res Date: 2011-09-15 Impact factor: 3.455
Authors: Tamiko Konishi; Maria Calvillo; Ai-She Leng; Jack Feng; Tony Lee; Hansen Lee; James Lafayette Smith; Shahid H Sial; Nancy Berman; Samuel French; Viktor Eysselein; Keh-Ming Lin; Yu-Jui Yvonne Wan Journal: Exp Mol Pathol Date: 2003-04 Impact factor: 3.362
Authors: Albert J Arias; Stephen Armeli; Joel Gelernter; Jonathan Covault; Antero Kallio; Sakari Karhuvaara; Tiina Koivisto; Rauno Mäkelä; Henry R Kranzler Journal: Alcohol Clin Exp Res Date: 2008-07 Impact factor: 3.455
Authors: Stephanie S O'Malley; Robert W Robin; Aryeh L Levenson; Iva GreyWolf; Lawrence E Chance; Colin A Hodgkinson; Denise Romano; Jane Robinson; Boris Meandzija; Verner Stillner; Ran Wu; David Goldman Journal: Alcohol Clin Exp Res Date: 2008-07 Impact factor: 3.455
Authors: Raymond F Anton; Gabor Oroszi; Stephanie O'Malley; David Couper; Robert Swift; Helen Pettinati; David Goldman Journal: Arch Gen Psychiatry Date: 2008-02
Authors: Adam Auton; Lisa D Brooks; Richard M Durbin; Erik P Garrison; Hyun Min Kang; Jan O Korbel; Jonathan L Marchini; Shane McCarthy; Gil A McVean; Gonçalo R Abecasis Journal: Nature Date: 2015-10-01 Impact factor: 49.962
Authors: Emily E Hartwell; Richard Feinn; Paige E Morris; Joel Gelernter; John Krystal; Albert J Arias; Michaela Hoffman; Ismene Petrakis; Ralitza Gueorguieva; Joseph P Schacht; David Oslin; Raymond F Anton; Henry R Kranzler Journal: Addiction Date: 2020-02-11 Impact factor: 6.526
Authors: Aaron C Lim; Dara G Ghahremani; Erica N Grodin; ReJoyce Green; Spencer Bujarski; Emily E Hartwell; Kelly E Courtney; Kent Hutchison; Karen Miotto; Lara A Ray Journal: Drug Alcohol Depend Date: 2019-05-09 Impact factor: 4.852
Authors: Lara A Ray; ReJoyce Green; Daniel J O Roche; Spencer Bujarski; Emily E Hartwell; Aaron C Lim; Taylor Rohrbaugh; Dara Ghahremani; Kent Hutchison; Karen Miotto Journal: Alcohol Clin Exp Res Date: 2018-02-01 Impact factor: 3.928